Search results for "Hypertensive"

showing 10 items of 250 documents

Efficacy and safety of tafluprost 0.0015% and timolol maleate 0.5% fixed combination in patients with ocular hypertension or open-angle glaucoma.

2014

Lowering intraocular pressure (IOP) is at present the only therapeutic approach to the treatment of glaucoma proven to be successful. The choice of therapy must take into account efficacy, tolerability, safety, quality of life, adherence and cost. Monotherapy fails to achieve a satisfactory IOP reduction in 40 - 75% of glaucoma patients after2 years of therapy. So far, three prostaglandin/timolol maleate 0.5% fixed combinations (FCs) are available.This review provides a background on the tafluprost-timolol FC (TTFC, Santen Oy) and its individual compounds. It summarizes the data on efficacy and safety, including comparative data with prostaglandin/timolol FCs already available.Tafluprost is…

Intraocular pressuregenetic structuresOpen angle glaucomaDrug-Related Side Effects and Adverse ReactionsOcular hypertensionTimololGlaucomamedicineHumansPharmacology (medical)Antihypertensive AgentsPharmacologybusiness.industryProstaglandins FTafluprostGlaucomaGeneral Medicinemedicine.diseaseeye diseasesDrug CombinationsProstaglandin analogTolerabilityAnesthesiaTimololDrug Evaluationlipids (amino acids peptides and proteins)Ocular Hypertensionsense organsbusinessGlaucoma Open-Anglemedicine.drugExpert opinion on pharmacotherapy
researchProduct

Intercurrent factors associated with the development of open-angle glaucoma in The European Glaucoma Prevention Study

2007

Purpose: To evaluate the intercurrent factors for the development of open-angle glaucoma (OAG) in ocular hypertensive patients who were enrolled in the European Glaucoma Prevention Study (EGPS). Design: Randomized, double masked, controlled clinical trial. Methods: setting: Multicenter. study population: A total of 1,077 patients fulfilled a series of inclusion criteria, including intraocular pressure (IOP) 22 to 29 mm Hg, normal and reliable visual fields (VFs) and normal optic disks. intervention: Treatment with dorzolamide or placebo. main outcome measures: Glaucoma-related VF or optic disk changes. Clinical data were collected every six months during a five-year follow-up. Proportional …

Intraocular pressuremedicine.medical_specialtyTime Factorsgenetic structuresOpen angle glaucomaSettore MED/06 - Oncologia MedicaOptic DiskOptic diskOcular hypertensionGlaucomaThiopheneslaw.inventionCorneaDouble-Blind MethodDorzolamideRandomized controlled trialRisk FactorslawOphthalmologyConfidence IntervalsPrevalencemedicineHumansDiureticsglaucoma ocular hypertension intercurrent risk factorsAntihypertensive AgentsIntraocular PressureProportional Hazards ModelsRetrospective StudiesSulfonamidesbusiness.industryHazard ratioRetinal Hemorrhagemedicine.diseaseeye diseasesEuropeOphthalmologyTreatment OutcomeCardiovascular Diseasessense organsbusinessGlaucoma Open-AngleFollow-Up Studiesmedicine.drug
researchProduct

Oesophagogastroduodenoscopy in patients with cirrhosis: Extending the range of detection beyond portal hypertension

2010

Background: Oesophagogastroduodenoscopy is currently recommended for the screening of varices in cirrhosis. In addition to the assessment of varices, oesophagogastroduodenoscopy can detect conditions that, while unrelated to portal hypertension, may require treatment. Aims: We evaluated in a large cohort of cirrhotic patients the prevalence of upper digestive findings other than oesophagogastric varices, the associations between upper gastrointestinal findings, portal hypertension and features of cirrhosis, and the incidence of new lesions in the course of a surveillance program. Methods: Analysis of the records of 611 consecutive cirrhotic patients undergoing oesophagogastroduodenoscopy fo…

Liver CirrhosisMalemedicine.medical_specialtyCirrhosisPepticPortal hypertensive gastropathyAdenocarcinomaEsophageal and Gastric VaricesGastroenterologyAsymptomaticHelicobacter InfectionsPolypsStomach NeoplasmsInternal medicineHypertension PortalPrevalenceHumansMedicineEndoscopy Digestive SystemStomach UlcerVascular DiseasesAgedMetaplasiaHelicobacter pyloriHepatologymedicine.diagnostic_testbusiness.industrycirrhosisIncidence (epidemiology)GastroenterologyMiddle Agedmedicine.diseaseEndoscopyDuodenal UlcerGastritisPortal hypertensionFemalemedicine.symptombusinessVaricesDigestive and Liver Disease
researchProduct

Vasoactive properties of antihypertensive lactoferrin-derived peptides in resistance vessels: Effects in small mesenteric arteries from SHR rats

2017

Aims: Bovine lactoferrin (LF) hydrolysates and peptides identified thereof have shown antihypertensive effects in rat models, mainly but not exclusively by angiotensin-converting enzyme inhibition. In this study we aimed to assess the vasoactive effects and mechanisms of an ultrafiltered (< 3 kDa) pepsin LF hydrolysate (LFH) and a heptapeptide identified in a LF hydrolysate produced by yeast proteolysis (DPYKLRP) in peripheral resistance arteries from spontaneously hypertensive rats (SHRs). Main methods: We used a myograph system for isometric tension recording in isolated small mesenteric arteries from SHRs. Direct vasoactive effects of LFH (30–100 μg/mL) and DPYKLRP (30–100 μM) were asses…

Male0301 basic medicinemedicine.medical_specialtyProtein HydrolysatesAntihypertensive effectsBlood PressureLactoferrin-derived peptidesIn Vitro TechniquesGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciencesSpontaneously hypertensive ratIn vivoRats Inbred SHRInternal medicinemedicineAnimalsGeneral Pharmacology Toxicology and PharmaceuticsPhenylephrineMesenteric arteriesAntihypertensive AgentsSpontaneously hypertensive rat030109 nutrition & dieteticsDose-Response Relationship Drugbiologybusiness.industryMesenteric arteryVasorelaxationGeneral MedicineAction mechanismMesenteric ArteriesVasodilationLactoferrinEndocrinologymedicine.anatomical_structureHypertensionbiology.proteinVascular ResistanceCyclooxygenaseSodium nitroprussidebusinessOligopeptidesAcetylcholinemedicine.drugMyograph
researchProduct

The prescription of direct oral anticoagulants in the elderly: An observational study of 19 798 Ambulatory subjects.

2020

International audience; Objective Direct oral anticoagulants (DOACs) are increasingly prescribed to elderly people, but the epidemiologic data for this population remains scarce. We compared the elderly population taking DOACs and those not taking DOACs (noDOAC). Method We included individuals over 75 years old, affiliated to Mutualite Sociale Agricole of Burgundy (a French regional health insurance agency), who had been refunded for a prescribed DOAC between 1st and 30th September 2017. The DAOC group (DAOCG) and noDOAC group (noDOACG) were compared in terms of demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs. In the DOACG, we compared the…

MaleAdministration Oral030204 cardiovascular system & hematologyKidney Function Tests0302 clinical medicineRivaroxabanMedicineDisease030212 general & internal medicineProspective StudiesPractice Patterns Physicians'Aged 80 and overeducation.field_of_studyFrailtyVenous ThromboembolismGeneral MedicineMetaanalysisManagement3. Good healthDabigatranHealthCreatinineAmbulatoryPlatelet aggregation inhibitorApixabanFemaleBlood Coagulation TestsFranceSafetymedicine.drugmedicine.medical_specialtyPyridonesPopulationDrug PrescriptionsDabigatran03 medical and health sciencesInternal medicineHumansMedical prescriptioneducationAntihypertensive AgentsAgedRivaroxabanbusiness.industryWarfarinAnticoagulantsBlood Cell CountAtrial-FibrillationChronic DiseasePyrazolesWarfarinbusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyPlatelet Aggregation InhibitorsInternational journal of clinical practiceREFERENCES
researchProduct

Combination Therapy with Oral Treprostinil for Pulmonary Arterial Hypertension:A Double-Blind Placebo-controlled Clinical Trial

2020

Rationale: Oral treprostinil improves exercise capacity in patients with pulmonary arterial hypertension (PAH), but the effect on clinical outcomes was unknown.\ud \ud Objectives: To evaluate the effect of oral treprostinil compared with placebo on time to first adjudicated clinical worsening event in participants with PAH who recently began approved oral monotherapy.\ud \ud Methods: In this event-driven, double-blind study, we randomly allocated 690 participants (1:1 ratio) with PAH to receive placebo or oral treprostinil extended-release tablets three times daily. Eligible participants were using approved oral monotherapy for over 30 days before randomization and had a 6-minute-walk dista…

MaleAdministration OralOral treprostinilCritical Care and Intensive Care MedicinePulmonary arterial hypertension[SDV.MHEP.PSR]Life Sciences [q-bio]/Human health and pathology/Pulmonology and respiratory tractcombination therapyoralepoprostenol0302 clinical medicinepulmonary arterial hypertensionmiddle agedClinical endpointdouble-blind methodMESH: Double-Blind MethodFamilial Primary Pulmonary Hypertension030212 general & internal medicinehumansMESH: AgedMESH: Middle AgedEpoprostenol/analogs & derivativesadultHazard ratioMiddle Aged[SDV.SP]Life Sciences [q-bio]/Pharmaceutical sciencesantihypertensive agents3. Good healthagedfemaleMESH: Young Adultoral treprostinilMESH: Administration Oralyoung adultFemalePulmonary Arterial Hypertension/drug therapymedicine.drugAdultPulmonary and Respiratory MedicineMESH: Pulmonary Arterial Hypertensionmedicine.medical_specialtyRandomizationAdolescentclinical study; combination therapy; oral treprostinil; pulmonary arterial hypertension; sequential therapy; administration oral; adolescent; adult; aged; antihypertensive agents; double-blind method; epoprostenol; female; humans; male; middle aged; placebos; pulmonary arterial hypertension; young adultSequential therapyMESH: PlacebosMESH: EpoprostenolLower riskPlaceboadministrationClinical studyYoung Adult03 medical and health sciencesDouble-Blind Method[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemmaleInternal medicineplacebosmedicineHumansCombination therapyAdverse effectPlacebos/therapeutic useAgedMESH: AdolescentPulmonary Vascular DiseaseMESH: Antihypertensive AgentsMESH: Humanssequential therapybusiness.industryMESH: AdultOriginal Articlesclinical studyMESH: MaleClinical trial030228 respiratory systemadolescentAntihypertensive Agents/administration & dosagebusinessMESH: FemaleTreprostinil
researchProduct

Efficacy and tolerability of lercanidipine in monotherapy in elderly patients with isolated systolic hypertension

2000

To investigate the efficacy and tolerability of lercanidipine, used as monotherapy once a day, in elderly patients with isolated systolic hypertension (ISH), 83 patients were enrolled in this multicenter, double-blind, randomized, placebo-controlled study. All patients were older than 60 years, and their mean age was 66.7 +/- 5.4 years. ISH was defined as SBPor = 160 mmHg, and DBP95 mmHg. After wash-out and placebo run-in periods, patients were randomly assigned to placebo or lercanidipine (10 mg once a day) treatment for 4 weeks. Non-responding patients of the lercanidipine-treated group were later treated with 20 mg of lercanidipine once a day for 4 additional weeks. At the end of the stu…

MaleAgingDihydropyridinesSystoleBlood PressurePlaceboPlacebo groupOrthostatic vital signsDouble-Blind MethodDiastoleHeart ratemedicineHumansAntihypertensive AgentsAgedbusiness.industryLercanidipineMiddle AgedBlood pressureTreatment OutcomeTolerabilityAnesthesiaIsolated systolic hypertensionHypertensionFemaleGeriatrics and Gerontologybusinessmedicine.drug
researchProduct

Changes in blood pressure in a large cohort of elderly individuals: Study 3C

2009

Summary Objective Analysis of changes in blood pressure with a two-year interval, and of factors associated with this change, in a large cohort of elderly individuals. Methods Follow-up of a cohort of 9294 individuals aged 65 years and over recruited from the general population for Study 3C. Changes in blood pressure are defined as the difference in its averages between the inclusion visit and the follow-up visit at 2 years. The factors associated with changes in systolic blood pressure were identified by univariate and multivariate analyses. Results Systolic and diastolic blood pressure decreased on average by 7.60 mmHg and 4.45 mmHg respectively in 7659 individuals included in the study b…

MaleAgingmedicine.medical_specialtyTime FactorsMultivariate analysisRégression vers la moyennePopulationPression artérielleHypertension artériellePredictive Value of TestsAntihypertensive treatmentRegression toward the meanInternal medicineEpidemiologymedicineHumanseducationRegression towards the meanTraitement antihypertenseurAntihypertensive AgentsAgedAged 80 and overeducation.field_of_studybusiness.industryAge FactorsCohortUnivariateReproducibility of ResultsBlood Pressure DeterminationGeneral MedicineCohorteBlood pressureMultivariate AnalysisHypertensionCohortBlood pressureCardiologyFemaleFranceElderly individualbusinessCardiology and Cardiovascular MedicineSujet âgéFollow-Up StudiesCohort studyArchives of Cardiovascular Diseases
researchProduct

Novel Antihypertensive Lactoferrin-Derived Peptides Produced by Kluyveromyces marxianus: Gastrointestinal Stability Profile and In Vivo Angiotensin I…

2014

Novel antihypertensive peptides released by Kluyveromyces marxianus from bovine lactoferrin (LF) have been identified. K. marxianus LF permeate was fractionated by semipreparative high performance liquid chromatography and 35 peptides contained in the angiotensin I-converting enzyme (ACE)-inhibitory fractions were identified by using an ion trap mass spectrometer. On the basis of peptide abundance and common structural features, six peptides were chemically synthesized. Four of them (DPYKLRP, PYKLRP, YKLRP, and GILRP) exerted in vitro inhibitory effects on ACE activity and effectively decreased systolic blood pressure after oral administration to spontaneously hypertensive rats (SHRs). Stab…

MaleAntihypertensive effectsAdministration OralAngiotensin-Converting Enzyme InhibitorsBlood PressurePeptideLactoferrin-derived peptidesPeptidyl-Dipeptidase AKluyveromycesKluyveromyces marxianusIn vivoRats Inbred SHRRenin–angiotensin systemAnimalsHumansKluyveromyces marxianusAmino Acid SequencePeptide sequenceAntihypertensive AgentsBiotransformationchemistry.chemical_classificationbiologyLactoferrinGastrointestinal digestionGeneral Chemistrybiology.organism_classificationAngiotensin IIRatsLactoferrinEnzymeBiochemistrychemistryHypertensionbiology.proteinCattlePeptidesGeneral Agricultural and Biological SciencesIn vivo ACE inhibition
researchProduct

Anti-hypertensive effects of Rosuvastatin are associated with decreased inflammation and oxidative stress markers in hypertensive rats

2009

International audience; Among their pleiotropic effects, statins exert antioxidant and anti-inflammatory properties. The aim of this study was to evaluate in normotensive (WKY) and in spontaneously hypertensive rats (SHR) the effect of rosuvastatin (ROSU) treatment on (1) plasma inflammation markers and endogenous NO synthase inhibitor (ADMA) levels, (2) reactive oxygen species (ROS) generated by circulating leukocytes and (3) vascular oxidative stress and tissue inflammation markers. Plasma cytokines were higher in SHR than in WKY, except for IL-4, which was lower in SHR than in WKY. SHR monocytes exhibited higher production of ROS than did WKY monocytes. In the experimental conditions, RO…

MaleAntioxidantmedicine.medical_treatmentBlood Pressure030204 cardiovascular system & hematologymedicine.disease_causeBiochemistryRats Inbred WKYchemistry.chemical_compound0302 clinical medicineRats Inbred SHR[SDV.IDA]Life Sciences [q-bio]/Food engineeringRosuvastatin CalciumComputingMilieux_MISCELLANEOUSchemistry.chemical_classification0303 health sciencesSulfonamidesGeneral Medicine3. Good healthNAD(P)H oxidasecardiovascular systemmedicine.symptommedicine.drugmedicine.medical_specialtyhypertensionleukocytesInflammationArgininestatins03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineAnimalsRosuvastatin[SPI.GPROC]Engineering Sciences [physics]/Chemical and Process Engineeringcardiovascular diseasesAntihypertensive Agents030304 developmental biologyInflammationReactive oxygen speciesCholesterolNAD(P)H oxidaseNADPH OxidasescytokinesRatsFluorobenzenesOxidative StressEndocrinologyBlood pressurePyrimidineschemistryInterleukin-4Hydroxymethylglutaryl-CoA Reductase InhibitorsReactive Oxygen SpeciesOxidative stress
researchProduct